BioCentury
ARTICLE | Clinical News

MVA-BN RSV: Completed Ph II enrollment

December 20, 2016 12:48 AM UTC

Bavarian Nordic completed enrollment of about 400 healthy volunteers ages ≥55 in a single-blind, placebo-controlled, U.S. Phase II trial evaluating 2 dose levels of MVA-BN RSV given once or twice 4 we...

BCIQ Company Profiles

Bavarian Nordic A/S

BCIQ Target Profiles

RSV F protein